Newsroom
Granza Bio grabs $7M seed from Felicis and YC to advance delivery of cancer treatments
“That conversation changed our lives,” Nandakumar said. “We decided we’re not joining Big Pharma. We’re going to make our own Big Pharma.”
Granza Bio Raises $7M+ Seed Funding to Advance the Delivery of Cancer Treatment and Genetic Medicines
Founded in 2024 by a team of cancer and immunology researchers at the University of Oxford, Granza Bio utilizes the discovery of "attack particles," a powerful suite of weapons in the immune system's arsenal that can fight diseases such as cancers, autoimmunity and infections.
Space for newcomers, biotech going mainstream, and more
Biotech startup Granza Bio is one of these and raised a $7 million seed from Felicis, Refactor, and Y Combinator to advance delivery of cancer treatments.
US-based Granza Bio raises $7M to advance cancer treatment delivery
Granza Bio, a San Francisco-based therapeutic delivery platform developer, raised $7.14 million in seed funding.
Comparison of different methods for isolating CD8+ T lymphocyte-derived extracellular vesicles and supramolecular attack particles
CD8+ T lymphocytes play vital roles in killing infected or deranged host cells, recruiting innate immune cells, and regulating other aspects of immune responses.
Comparison of different methods for isolating CD8+ T lymphocyte-derived extracellular vesicles and supramolecular attack particles
CD8+ T lymphocytes play vital roles in killing infected or deranged host cells, recruiting innate immune cells, and regulating other aspects of immune responses.
Supramolecular attack particles are autonomous killing entities released from cytotoxic T cells
Cytotoxic T cells (CTLs) are at the front lines against cancer and chronic infection. T cells kill by secreting caspase-activating granzymes and the pore-forming protein perforin from dense core granules.